7326. Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer.
作者: Aditya Bardia.;Sara A Hurvitz.;Sara M Tolaney.;Delphine Loirat.;Kevin Punie.;Mafalda Oliveira.;Adam Brufsky.;Sagar D Sardesai.;Kevin Kalinsky.;Amelia B Zelnak.;Robert Weaver.;Tiffany Traina.;Florence Dalenc.;Philippe Aftimos.;Filipa Lynce.;Sami Diab.;Javier Cortés.;Joyce O'Shaughnessy.;Véronique Diéras.;Cristiano Ferrario.;Peter Schmid.;Lisa A Carey.;Luca Gianni.;Martine J Piccart.;Sibylle Loibl.;David M Goldenberg.;Quan Hong.;Martin S Olivo.;Loretta M Itri.;Hope S Rugo.; .
来源: N Engl J Med. 2021年384卷16期1529-1541页
Patients with metastatic triple-negative breast cancer have a poor prognosis. Sacituzumab govitecan is an antibody-drug conjugate composed of an antibody targeting the human trophoblast cell-surface antigen 2 (Trop-2), which is expressed in the majority of breast cancers, coupled to SN-38 (topoisomerase I inhibitor) through a proprietary hydrolyzable linker.
7327. Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination.
作者: Marie Scully.;Deepak Singh.;Robert Lown.;Anthony Poles.;Tom Solomon.;Marcel Levi.;David Goldblatt.;Pavel Kotoucek.;William Thomas.;William Lester.
来源: N Engl J Med. 2021年384卷23期2202-2211页
The mainstay of control of the coronavirus disease 2019 (Covid-19) pandemic is vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Within a year, several vaccines have been developed and millions of doses delivered. Reporting of adverse events is a critical postmarketing activity.
|